Trial Profile
An Open-Label, Phase 2 Efficacy Study With Window of Opportunity Immune Assessment of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 17 Aug 2022 Planned End Date changed from 1 Jun 2022 to 1 Apr 2023.
- 17 Aug 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Apr 2023.
- 12 Jan 2022 Status changed from recruiting to active, no longer recruiting.